Meda Pharms patents expiration
1. Astepro patents expiration
ASTEPRO Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | MEDA PHARMS | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(1 year, 6 months from now) | |
| US8071073 | MEDA PHARMS | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2012 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 August, 2009
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED;NASAL
How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage
ASTEPRO family patents
2. Reglan Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6024981 | MEDA PHARMS | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
| US6221392 | MEDA PHARMS | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 June, 2005
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
More Information on Dosage
REGLAN ODT family patents